Ned Sharpless' 'brainchild' nabs a speedy FDA review for small cell lung cancer drug
It was animal data on G1 Therapeutics’ oncology drug trilaciclib that originally attracted current CEO Mark Velleca to the company six years ago. And now the 5-year clinical sojourn — a quick turn in the R&D world — is nearing the initial goal line at the FDA.
On Monday, G1 — which was co-founded by NCI chief Ned Sharpless — announced the drug was granted priority review by the FDA for patients with small cell lung cancer. If approved, the company hopes to roll out trilaciclib early next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.